DISSECTION 2.0

Research Project
|
01.02.2025
- 31.01.2029

Whether pelvic lymph node dissection during radical prostatectomy offers an oncological benefit remains unknown. This study will compare extended pelvic lymph node dissection versus no dissection in PSMA PET-negative, Grade Group 2 and PSA > 20 ng/ml or Grade Group 3 or higher prostate cancer patients scheduled for surgery. The study will be conducted across all major urological clinics in Switzerland.

Funding

DISSECTION 2.0 - extended pelvic lymphadenectomy (ePLND) versus no ePLND during radical prostatectomy in high-risk, localized prostate cancer: a prospective randomized phase III study

Oncosuisse / Krebsliga Schweiz / Stiftung Krebsforschung Schweiz, 04.2024-03.2028 (48)

PI : Rentsch, Cyrill A..

Members (8)

Guillaume Nicolas

Nuclear medicine

Cyrill A. Rentsch

Owner

Stefanie Hayoz

Statistics

Alexandros Papachristofilou

George N. Thalmann

Richard Cathomas

Research Groups

Research Group Emanuel Christ

Translational Urogenital Cancer Research Group